Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 1 Woche 4 Tage
@MorphoSys
Gantenerumab - New Phase 3 Clinical Trials by
MorphoSys’s Partner now Underway https://t.co/D81jBaKgpx $MPSYF
vor 2 Monate 5 Tage
@MorphoSys
Yesterday, successful 1st trading day @Nasdaq #MorphoSysIPO https://t.co/lPBbaQYrbC
vor 2 Monate 6 Tage
@MorphoSys
MorphoSys IPO at Nasdaq. First day trading in the U.S. - watch the Bell Ringing Ceremony today at 9.30am EDT (3:30p… https://t.co/lJ6WhNFXBZ
vor 3 Monate 1 Woche
@MorphoSys
MOR208 L-MIND update: results reported today confirm previously reported interim data in r/r DLBCL https://t.co/GbGaSvbRJe $MPSYF
vor 3 Monate 1 Woche
@MorphoSys
MorphoSys presents results for FY2017, guidance fully met, revenues including 1st royalties on Tremfya(R) https://t.co/dosdQbwF1w $MPSYF
vor 4 Monate 1 Woche
@MorphoSys
Ph1 results in atopic dermatitis of IL-17C antibody MOR106 jointly
developed by MOR and GLPG to be presented in lat… https://t.co/RYVDqsZqMK
vor 6 Monate 2 Wochen
@MorphoSys
MorphoSys presents data on MOR208 L-MIND-Study at #ASH2017, see press release https://t.co/rO8EoSsOLK, see poster… https://t.co/mJRALiHtLf
vor 6 Monate 3 Wochen
@MorphoSys
3rd approval! In addition to the U.S. and EU, Janssen's Tremfya® (guselkumab) approved for the treatment of moderat… https://t.co/3a0l42CZ6q
vor 6 Monate 3 Wochen
@MorphoSys
MorphoSys signs regional license agreement for MOR202 with I-Mab for Greater China, MorphoSys receives USD 20m upfr… https://t.co/3CjngYOkvn
vor 7 Monate 3 Tage
@MorphoSys
Janssen's Tremfya® approved in Europe for plaque psoriasis; first HuCAL-antibody to become available to patients in… https://t.co/FQ5gc1AukK
Medien und Investoren
Corporate Communications und Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
E-Mail Kontakt